Clinical Trial

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Name: Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia — clinical trial record (NCT07680946)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by positive and negative syndrome scale (PANSS) total score in participants with schizophrenia.

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-22

Trial Details

NCT Number	NCT07680946
Lead Sponsor	TG Therapeutics, Inc.
Conditions	Schizophrenia
Enrollment	60 participants
Start Date	2026-07-03
Primary Completion	2028-12-01 (estimated)
Study Completion	2029-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-21